Enterprise Value
-210.8M
Cash
541.5M
Avg Qtr Burn
-23.85M
Short % of Float
3.69%
Insider Ownership
9.58%
Institutional Own.
66.88%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 3 Data readout | ||
Bemnifosbuvir + Ruzasvir (RZR) Details Hepatitis C | Phase 2 Data readout | |
Failed Discontinued | ||
AT-752 Details Infectious disease, Dengue Fever | Failed Discontinued |